Medtronic (MDT) is back in focus after releasing SPYRAL AFFIRM study results on its Symplicity Spyral renal denervation system and securing updated FDA labeling that broadens the supporting clinical data for several high risk hypertension groups.
Recent momentum around Medtronic reflects that mix of clinical news and expectations, with the share price up 20.4% over the past month and the 1 year total shareholder return at 20.3%, suggesting buyers have been leaning in. Meanwhile, the 3 year total shareholder return of 65.0%, versus a far more modest 5 year total shareholder return of 2.9%, points to strong medium term gains that have only more recently rebuilt after a slower longer run.
Scan how Medtronic's move fits alongside other healthcare leaders showing fresh momentum by checking our curated list of 32 resilient stocks with low risk scores .
After a 20% jump in a month, Medtronic now trades almost exactly on the US$104.62 analyst target while our intrinsic value gauge still shows a 5% gap. Where does fair value really fall in that spread?
Most Popular Narrative: 9% Undervalued
The most followed thesis on Medtronic pegs fair value at $115.38, comfortably above the last close at $104.84, and frames the recent move as only part of the story according to LunaRodas.
The phrase "inflection point" or its equivalents have orbited Medtronic's transcript language for several quarters. This quarter, management moved to secure the claim. Martha's closing remarks to the analyst who asked whether the "mid-single-digit revenue grower, high single-digit EPS" characterization of Medtronic still holds: "Clearly, we have aspirations for higher growth than we've done historically... we're not satisfied with that." The framing is not a promise of specific targets. Investor Day in December is where those will be disclosed. It is the first time management has used analyst-facing language to explicitly distance the company from its own historical growth ceiling.
See why 11 investors see Medtronic as 9% undervalued .
Result: Fair Value of $115.38 (UNDERVALUED)
Still, the Medtronic story can break if execution on MiniMed separation slips or if renal denervation adoption cools after the current SPYRAL spotlight.
Find out about the key risks to this Medtronic narrative .
Next Steps
With sentiment leaning positive around Medtronic, this is the moment to pressure test the narrative against the underlying metrics yourself. To see which potential upsides others are focused on, review the 5 key rewards .
Looking for more investment ideas beyond Medtronic?
If Medtronic sits in your portfolio or watchlist already, use this momentum as a cue to line up your next candidates with a focused screener shortlist.
-
Target potential mispricing by scanning companies that currently feature in our 42 high quality undervalued stocks .
-
Zero in on income opportunities by reviewing a hand picked set of 6 dividend fortresses .
-
Prioritise resilience and financial strength by working through a list of solid balance sheet and fundamentals (24 results) .
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MDT .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
